title: Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: multicenter study interim report.
abstract: One hundred sixteen patients with superficial bladder cancers (Stages Ta, T1, and TIS) were evaluated and treated with either intravesical bacillus Calmette-Guerin [Tice strain] (BCG) or doxorubicin hydrochloride (Adriamycin [ADR]), in a multicenter study. One hundred nine of these patients currently have follow-up. Of these, 54 were completely resected and 55 incompletely resected. For complete resections, based on recurrence rates per 100 patient months, both BCG (0.22) and ADR (0.91) worked well, although BCG had a slightly lower recurrence rate. However, for incomplete resections, BCG (0.20) had a markedly lower recurrence rate than ADR (2.52). Eighteen patients failed initial treatment, with either BCG or ADR. All have been placed on long-term therapy schedules. Of the 12 failures who currently have follow-up, 11 (92%) have either partially or completely responded with additional intravesical therapy. No patients in this study have yet required cystectomies.
authors.affiliation: Department of Surgery, Hahnemann University, Philadelphia, Pennsylvania.
authors.forename: O P
authors.initials: OP
authors.lastname: Khanna
authors.forename: D L
authors.initials: DL
authors.lastname: Son
authors.forename: H
authors.initials: H
authors.lastname: Mazer
authors.forename: J
authors.initials: J
authors.lastname: Read
authors.forename: D
authors.initials: D
authors.lastname: Nugent
authors.forename: R
authors.initials: R
authors.lastname: Cottone
authors.forename: M
authors.initials: M
authors.lastname: Heeg
authors.forename: M
authors.initials: M
authors.lastname: Rezvan
authors.forename: N
authors.initials: N
authors.lastname: Viek
authors.forename: M
authors.initials: M
authors.lastname: Friedmann
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D012074:Remission Induction; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D004317:Doxorubicin